Traduction de «the number of reports » (Néerlandais → Français) :

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events
Reactions and events reported in 2006 were analysed and summarized in a first annual report which gives an overview of the notifications, the most important findings and a number of recommendations ●● In 2007 a total of 848 reactions and events

In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.
In this first “annual report”, we have chosen to describe the transition from the DG Medicinal Products of the FPS Public Health to an autonomous medicines agency and provide more details about a number of activities in 2007.

The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.
The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.

In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 21 .
In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 22 .

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.

De resultaten uit de studies werden zonodig omgezet naar dezelfde eindmetingen, met name " absolute risk reduction" (ARR) en " number needed to treat" (NNT).
Les résultats ont été extraits des études et, le cas échéant, convertis dans les mêmes instruments de mesure, à savoir : réduction absolue du risque (ARR) et nombre de sujets à traiter (NNT).

De voorgelegde resultaten en het daaruit berekende " number needed to treat" (NNT – te behandelen aantal mensen om 1 extra roker te doen stoppen) hebben alleen betrekking op mensen met een vergelijkbare motivatie.
Les résultats présentés et le nombre de sujets à traiter (number needed to treat - NNT) se rapportent uniquement à des populations ayant une motivation comparable.

Dit absolute verschil van 7% rokers die stoppen geeft een " number needed to treat" (te behandelen aantal) van 14 weer, wat betekent dat 14 patiënten moeten worden behandeld met NVT om één extra roker te doen stoppen met roken na minstens 6 maanden, in tegenstelling tot placebo.
Cette différence absolue de 7 % dÊabstinence reflète un nombre de patients à traiter (NNT) de 14, autrement dit, il faut 14 patients traités par TNS pour obtenir un abstinent supplémentaire après 6 mois, comparé au placebo.

De resultaten werden indien nodig omgezet naar dezelfde uitkomstmaten, met name „absolute risk reduction‰ (ARR) en „number needed to treat‰ (NNT, te behandelen aantal).
Les résultats ont été extraits des études et, le cas échéant, convertis dans les mêmes instruments de mesure, à savoir : réduction absolue du risque (ARR et nombre de sujets à traiter (NNT).